| abstract |
The invention is directed to physiologically active compounds of general formula (I): wherein Het is an optionally substituted, saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N; R1 is optionally substituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; Z1 i s NR5; L1 is a -R6-R7- linkage (where R6 is alkylene, alkenylene or alkynylene and R7 is a direct bond, cycloalkylene, heterocycloalkylene, aryldiyl, heteroaryldiyl, -C(=Z3)-NR5-, -NR5-C(=Z3)-, -Z3-, -C(=O)-, -C(=NOR5)-, -NR5- , - NR5-C(=Z3)-NR5-, -SO2-NR5-, -NR5-SO2-, -O-C(=O)-, -C(=O)-O-, -NR5-C(=O)-O- o r - O-C(=O)-NR5-); L2 is an alkylene chain substituted by hydroxy, oxo, -OR4, -O - C(=O)-R4, -N(R8)-C(=O)-R9, -N(R8)-C(=O)-OR9, -N(R8)-SO2-R9, or -NY3 Y4; and Y is carboxy or an acid bioisostere; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compoun ds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (.alpha.4.beta.1) |